Bicycle Therapeutics plc (NASDAQ:BCYC) Director Acquires $7,670,000.00 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) Director Bros. Advisors Lp Baker bought 500,000 shares of the stock in a transaction on Monday, December 16th. The shares were acquired at an average cost of $15.34 per share, with a total value of $7,670,000.00. Following the acquisition, the director now directly owns 9,995,274 shares in the company, valued at approximately $153,327,503.16. This trade represents a 5.27 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Friday, December 13th, Bros. Advisors Lp Baker bought 985,397 shares of Bicycle Therapeutics stock. The stock was bought at an average cost of $13.76 per share, for a total transaction of $13,559,062.72.

Bicycle Therapeutics Stock Up 0.1 %

BCYC opened at $15.14 on Wednesday. The business has a 50 day moving average of $22.62 and a 200-day moving average of $22.71. Bicycle Therapeutics plc has a 12-month low of $12.17 and a 12-month high of $28.67. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -4.60 and a beta of 0.86.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. During the same period last year, the business posted ($1.26) earnings per share. The business’s revenue for the quarter was down 50.0% compared to the same quarter last year. As a group, analysts expect that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of institutional investors have recently modified their holdings of BCYC. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Bicycle Therapeutics by 0.6% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock worth $17,975,000 after purchasing an additional 4,976 shares during the period. Pinnacle Associates Ltd. lifted its position in Bicycle Therapeutics by 202.2% during the second quarter. Pinnacle Associates Ltd. now owns 242,001 shares of the company’s stock worth $4,898,000 after purchasing an additional 161,911 shares during the period. Natixis Advisors LLC bought a new stake in Bicycle Therapeutics during the second quarter worth about $261,000. TD Asset Management Inc grew its stake in Bicycle Therapeutics by 76.7% during the second quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock worth $1,967,000 after buying an additional 42,200 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Bicycle Therapeutics by 97.2% in the second quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock valued at $6,614,000 after acquiring an additional 161,100 shares during the last quarter. Institutional investors own 86.15% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on BCYC. HC Wainwright lowered their target price on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research note on Monday. Stephens began coverage on shares of Bicycle Therapeutics in a report on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a research note on Monday, September 16th. B. Riley cut their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.